Validation of tissue microarray technology in ovarian carcinoma

被引:100
作者
Rosen, DG
Huang, XL
Deavers, MT
Malpica, A
Silva, EG
Liu, JS
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
关键词
ovarian carcinoma; tissue microarrays; validation; immunohistochemistry; Ki-67; estrogen receptors; p53;
D O I
10.1038/modpathol.3800120
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
High-throughput tissue microarray allows many clinical specimens to be analyzed simultaneously on a single slide. One potential limitation of tissue microarray is the correct representation of each tumor with the small tissue core. Because tumors from different organs have different levels of heterogeneity, it requires a validation study for each one of them. We compared immunostaining of Ki-67, estrogen receptors, and p53 in whole sections of 45 cases of high-grade serous ovarian carcinoma with six core samples from those sections with regard to the number of tissue cores needed to reliably represent a whole section. Staining for Ki-67 was graded high or low by automated image analysis of 10 high-power fields; staining for estrogen receptor and p53 was scored on a 0-to-3 scale. Correlation coefficients for whole-section vs core stains were 0.86 for Ki-67, 0.93 for estrogen receptors, and 0.82 for p53. A total of 54 (6.6%) of the cores were inadequate for scoring. The probability that results from one core would correctly represent all three markers in the whole section was 91%; that for two cores was 96%; and that for three cores was 98%. Our results show that analysis of a single readable core matched the staining pattern of a whole section more than 90% of the time, and analysis of two cores increased that value to more than 95%, demonstrating that ovarian carcinoma tissue microarray is a reliable technique to analyze the expression of markers.
引用
收藏
页码:790 / 797
页数:8
相关论文
共 28 条
[1]  
BATTIFORA H, 1986, LAB INVEST, V55, P244
[2]  
Benda JA., 1994, GYNECOL ONCOL
[3]   Tissue microarray (TMA) technology:: miniaturized pathology archives for high-throughput in situ studies [J].
Bubendorf, L ;
Nocito, A ;
Moch, H ;
Sauter, G .
JOURNAL OF PATHOLOGY, 2001, 195 (01) :72-79
[4]   Validation of tissue microarray technology in breast carcinoma [J].
Camp, RL ;
Charette, LA ;
Rimm, DL .
LABORATORY INVESTIGATION, 2000, 80 (12) :1943-1949
[5]  
Fernebro E, 2002, ARCH PATHOL LAB MED, V126, P702
[6]  
Gillett CE, 2000, J PATHOL, V192, P549
[7]   Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays [J].
Gulmann, C ;
Butler, D ;
Kay, E ;
Grace, A ;
Leader, M .
HISTOPATHOLOGY, 2003, 42 (01) :70-76
[8]   Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations [J].
Hoos, A ;
Cordon-Cardo, C .
LABORATORY INVESTIGATION, 2001, 81 (10) :1331-1338
[9]   Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors [J].
Hoos, A ;
Urist, MJ ;
Stojadinovic, A ;
Mastorides, S ;
Dudas, ME ;
Leung, DHY ;
Kuo, D ;
Brennan, MF ;
Lewis, JJ ;
Cordon-Cardo, C .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (04) :1245-1251
[10]   The application of tissue microarrays to cancer research [J].
Horvath, L ;
Henshall, S .
PATHOLOGY, 2001, 33 (02) :125-129